Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann MacLaren

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nurse Education in Practice|October 2, 2017
Supporting nurse mentor development: An exploration of developmental constellations in nursing mentorship practiceJulie-Ann MacLaren
Radiation Research|September 24, 2009
Chk2 protects against radiation-induced genomic instabilityAnn MacLaren, Daniela Slavin, Clare H McGowan
Nurse Education in Practice|August 29, 2020
Co-production of an intervention to increase retention of early career nurses: Acceptability and feasibilityJudy Brook, Leanne Aitken, Dr Julie-Ann MacLaren, et al.
BMC Nursing|January 13, 2021
An intervention to decrease burnout and increase retention of early career nurses: a mixed methods study of acceptability and feasibilityJudy Brook, Leanne M Aitken, Julie-Ann MacLaren, et al.
Cellular Signalling|April 17, 2002
Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factorCatherine Dunn, Carolyn Wiltshire, Ann MacLaren, et al.
Molecular and Cellular Biology|October 1, 2004
c-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulationAnn MacLaren, Elizabeth J Black, William Clark, et al.
Oncogene|September 13, 2002
Cell transformation by v-Jun deactivates ERK MAP kinase signallingElizabeth J Black, Mark Walker, William Clark, et al.
British Journal of Haematology|April 8, 2017
Marizomib for central nervous system-multiple myelomaAshraf Badros, Zeba Singh, Binod Dhakal, et al.
Neuro-Oncology|December 19, 2015
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrierKaijun Di, G Kenneth Lloyd, Vivek Abraham, et al.
British Journal of Haematology|October 28, 2017
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study resultsAndrew Spencer, Simon Harrison, Jeffrey Zonder, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nurse Education in Practice|October 2, 2017
Supporting nurse mentor development: An exploration of developmental constellations in nursing mentorship practiceJulie-Ann MacLaren
Radiation Research|September 24, 2009
Chk2 protects against radiation-induced genomic instabilityAnn MacLaren, Daniela Slavin, Clare H McGowan
Nurse Education in Practice|August 29, 2020
Co-production of an intervention to increase retention of early career nurses: Acceptability and feasibilityJudy Brook, Leanne Aitken, Dr Julie-Ann MacLaren, et al.
BMC Nursing|January 13, 2021
An intervention to decrease burnout and increase retention of early career nurses: a mixed methods study of acceptability and feasibilityJudy Brook, Leanne M Aitken, Julie-Ann MacLaren, et al.
Cellular Signalling|April 17, 2002
Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factorCatherine Dunn, Carolyn Wiltshire, Ann MacLaren, et al.
Molecular and Cellular Biology|October 1, 2004
c-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulationAnn MacLaren, Elizabeth J Black, William Clark, et al.
Oncogene|September 13, 2002
Cell transformation by v-Jun deactivates ERK MAP kinase signallingElizabeth J Black, Mark Walker, William Clark, et al.
British Journal of Haematology|April 8, 2017
Marizomib for central nervous system-multiple myelomaAshraf Badros, Zeba Singh, Binod Dhakal, et al.
Neuro-Oncology|December 19, 2015
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrierKaijun Di, G Kenneth Lloyd, Vivek Abraham, et al.
British Journal of Haematology|October 28, 2017
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study resultsAndrew Spencer, Simon Harrison, Jeffrey Zonder, et al.
Pageof 1